Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piceid + resveratrol is a combination of two related stilbenoid polyphenols. Piceid, also known as polydatin, is the 3-beta-D-glucoside of resveratrol and serves as its primary natural precursor. While piceid is often converted to resveratrol in the gastrointestinal tract via glycosidases, it also exhibits distinct pharmacokinetic properties, including potentially higher oral bioavailability due to active transport mechanisms. Together, these compounds act as potent antioxidants and anti-inflammatory agents. Their primary mechanism of action involves the activation of Sirtuin 1 (SIRT1), a NAD+-dependent deacetylase associated with longevity and metabolic regulation, and the inhibition of pro-inflammatory pathways such as NF-kappaB and cyclooxygenase (COX) enzymes. This combination is frequently utilized in dietary supplements derived from *Polygonum cuspidatum* (Japanese Knotweed) for indications including cardiovascular health, metabolic syndrome, and neuroprotection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piceid + resveratrol.